Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Decreases By 33.9%

Achilles Therapeutics plc (NASDAQ:ACHLGet Free Report) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 90,300 shares, a drop of 33.9% from the November 30th total of 136,700 shares. Based on an average trading volume of 163,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the company’s stock are sold short.

Institutional Trading of Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd lifted its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHLFree Report) by 239.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,660 shares of the company’s stock after buying an additional 36,441 shares during the period. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 at the end of the most recent reporting period. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Achilles Therapeutics Stock Down 1.7 %

Shares of NASDAQ ACHL opened at $1.13 on Monday. The firm has a market cap of $46.44 million, a P/E ratio of -0.68 and a beta of 1.37. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.76. The company has a 50 day moving average of $1.04 and a 200 day moving average of $0.91.

About Achilles Therapeutics

(Get Free Report)

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.

Recommended Stories

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.